The HER2-low and HER2-ultralow breast cancer subtype designations have led to a changed landscape in HER2-directed therapies, ...

*仅供医学专业人士阅读参考近30%的早期乳腺癌患者在术前活检与新辅助治疗后残留病变之间的HER2表达会发生变化，并且仅HER2阳性向阴性的转变具有预后意义。乳腺癌是导致女性癌症相关死亡的主要原因之一。在浸润性乳腺癌病例中，人表皮生长因子受体2（HER ...

Drs Kathy Miller and Francisco J. Esteva discuss testing and therapeutic options for the new classification of HER2-ultra-low breast cancer.

New DESTINY-Breast06 analysis showed trastuzumab deruxtecan doubled PFS versus chemotherapy in patients with rapid ...

[1]Tarantino P, Hamilton E, Tolaney SM, et al. HER2-Low Breast Cancer: Pathological and Clinical Landscape. J Clin Oncol. 2020;38(17):1951-1962. [2]Marty M, Cognetti F, Maraninchi D, et al ...

The most-read breast cancer articles include topics on hereditary breast cancer, hormone therapy benefits, BRCA mutations, as ...

Among patients with hormone receptor (HR)-positive, HER2-negative, low-risk ductal carcinoma in situ (DCIS), those who ...

A multicenter phase II trial has demonstrated that a combination of pyrotinib and fulvestrant offers significant antitumor ...

WEILL CORNELL MEDICINE PRESENTS HER2 PARSORTIX WORKFLOW AT SAN ANTONIO BREAST CANCER SYMPOSIUM. Independent findings support ANGLE's HER2 assay development programme. Potential fo ...